anticoagulant treatment at high doses, it can reduce the death rate by 30% and the need for intubation by 25% in hospitalized coronavirus patients who are not critically ill compared to standard of care, What is low-dose anticoagulation?. These are the conclusions of the international study ‘Freedom COVID’, which was presented this Monday as part of the American Congress of Cardiology in New Orleans (United States). An investigation coordinated by the HM Hospitals Research Foundation (FiHM) and that, they emphasize from the private clinic group, it can change the existing management of non-critical coronavirus patients.
In the study 76 hospitals from ten countries took part. In Spain, was managed by the HM Hospitales Research Foundation, with its Scientific Director, dr Jose Maria Castellano, as chief investigator. FiHM coordinated the centers and patients involved in the research, which, explains Dr. Castellano, provides new insights into optimizing the management of Covid-19 patients and shows that high-dose anticoagulation can do this improve survival, especially in hospitalized patients with lung involvement with no indication of intensive care.
The main author of “Freedom” is the doctor Valentin FusterDirector General of the National Center for Cardiovascular Research (CNIC), President of Mount Sinai Heart and Chief Physician of Mount Sina Hospitali (New York), who published the results of this study – published by the Journal of American College of Cardiology (JACC) – in American College of Cardiology.
Five Spanish hospitals
At the beginning of the pandemic, doctor recognized Valentin Fuster that many hospital patients with COVID-19 a high level of blood clots developed life-threatening and chose to start this study between August 2020 and September 2022. 3,398 adult patients were recruited Hospitalizations with coronavirus (with a median age of 53 years) from 76 hospitals in 10 countries, including Spain.
The patients were not admitted In intensive care or intubated, and about half showed signs of the disease affecting and causing their lungs acute lung failure (ACUTE LUNG FAILURE). “This is the first study to show that high-dose anticoagulation can improve survival in this patient population, an important finding as deaths from Covid-19 remain common,” said the cardiologist.
The participants were randomized Receive doses of three different types of blood thinners within 24-48 hours of hospital admission and 30 days were observed. Their follow-up showed that treatment with prophylactic anticoagulation (at low doses) was associated with better outcomes, both in and out of intensive care, among patients hospitalized for coronavirus. Researchers also noted that therapeutic (high-dose) anticoagulation might lead to better outcomes.
The participation of the FiHM served as a liaison to manage the cohort of patients from five Spanish hospitals: HM Sanchinarro, HM Montepríncipe, HM Torrelodones and two public ones, the Complejo Hospitalario de Navarra and the Infanta Leonor University Hospital, in Vallecas, Madrid. HM Hospitales Group, through FiHM, highlights that it has participated in most of the clinical trials that have provided evidence of both the treatments currently indicated in patients with coronavirus as with the various vaccines in adults, children and pregnant women.